Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-05-11FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for quetiapine fumarate from Aurobindo Pharma Limited, enabling generic production under an Abbrevia…
-
FDA approval · 2023-05-11FDA Approved: QUETIAPINE — Supplemental Application (Ascend Laboratories, LLC)
The FDA granted a supplemental approval for Quetiapine (generic) from Ascend Laboratories, LLC, approving an additional application for this…
-
FDA approval · 2023-05-10FDA Approved: REXULTI — Supplemental Application (Otsuka America Pharmaceutical, Inc.)
The FDA approved a supplemental application for Rexulti (brexpiprazole) submitted by Otsuka America Pharmaceutical, Inc., resulting in chang…
-
FDA approval · 2023-04-28FDA Approved: UZEDY — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved UZEDY (risperidone) through an original application from Teva Pharmaceuticals USA, Inc. for the treatment of schizophrenia, bip…
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia [Phase 3]
Phase 3 clinical trial evaluating Roluperidone (MIN-101) for negative symptoms of schizophrenia has completed and results were posted in 202…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-04-26FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Haloperidol Decanoate by Hikma Pharmaceuticals USA Inc., authorizing changes under an existi…
-
FDA label_change · 2023-04-26FDA Approved: VERSACLOZ — Supplemental Application (TruPharma LLC)
FDA notes a supplemental application for Versacloz (clozapine) by TruPharma LLC, indicating a labeling change or amendment to the approved p…
-
FDA approval · 2023-04-26FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for Clozapine filed by Mylan Pharmaceuticals Inc., enabling continued generic availability under…
-
FDA approval · 2023-04-26FDA Approved: CLOZAPINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Clozapine from Teva Pharmaceuticals USA, Inc., updating its labeling to reflect new information.
-
CLINICAL_TRIALS trial_result · 2023-04-26Clinical Trial Update: A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients [Phase 2]
A Phase 2 clinical trial evaluating sulforaphane in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Feasibility Electrical Stimulation Study for Visual Hallucinations [NA]
A completed feasibility study evaluating electrical stimulation for visual hallucinations in schizophrenia, schizoaffective disorder, and bi…
-
FDA approval · 2023-04-20FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Ingenus Pharmaceuticals, LLC)
FDA approved a supplemental application for quetiapine fumarate from Ingenus Pharmaceuticals, LLC, marking an additional approval/modificati…
-
FDA approval · 2023-04-19FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for quetiapine fumarate from Aurobindo Pharma Limited, authorizing a generic version under an ANDA.
-
FDA approval · 2023-04-19FDA Approved: QUETIAPINE — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for quetiapine from Solco Healthcare U.S., LLC to authorize a generic version of the drug for the U.…
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia [Phase 1]
Phase 1 trial update examining the effect of LY2140023 (pomaglumetad methionil) on ECGs in participants with schizophrenia; study completed …
-
FDA approval · 2023-03-30FDA Approved: FLUPHENAZINE DECANOATE — Original Application (Sagent Pharmaceuticals)
The FDA approved a generic fluphenazine decanoate long-acting injectable from Sagent Pharmaceuticals under an Original Application, enabling…
-
FDA label_change · 2023-03-27FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for haloperidol decanoate, updating the labeling for the product.
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness [NA]
Completed clinical trial evaluating skills training to improve vocational outcomes in veterans with serious mental illness; results posted i…
-
FDA approval · 2023-03-22FDA Approved: OLANZAPINE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for a generic olanzapine product. The approval enables marketing of the olanzapine…
-
CLINICAL_TRIALS research · 2023-03-17Clinical Trial Update: Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU) [Phase 4]
A Phase 4 clinical trial examining how structural and myelin abnormalities relate to cognitive impairments in recent-onset schizophrenia bef…
-
CLINICAL_TRIALS trial_result · 2023-03-13Clinical Trial Update: tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia [NA]
Clinical trial on transcranial direct current stimulation plus cognitive training for chronic smokers with schizophrenia; status TERMINATED …
-
FDA approval · 2023-03-10FDA Approved: LURASIDONE HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's original ANDA for lurasidone hydrochloride, a generic antipsychotic indicated for schizophrenia and …
-
FDA approval · 2023-03-01FDA Approved: PALIPERIDONE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application to bring a generic paliperidone product to market.
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Translational Neuroscience Optimization of GlyT1 Inhibitor [Phase 2]
Phase 2 clinical trial evaluating a glycine transporter 1 (GlyT1) inhibitor for cognitive impairment in schizophrenia has completed, with re…
-
FDA approval · 2023-02-24FDA Approved: OLANZAPINE — Original Application (Modavar Pharmaceuticals LLC)
The FDA approved Modavar Pharmaceuticals LLC's original application for olanzapine, a generic antipsychotic. It is approved for the treatmen…